(2005). Blennow K: CSF biomarkers for mild cognitive impairment and early Alzheimer’sd i s e a s e .Clin Neurol Neurosurg
(2007). Blennow K: Prediction of Alzheimer’s disease using the CSF Abeta42/ Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord
(1997). Braak E: Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging
(2002). C: strucchange: An R package for testing for structural change in linear regression models.
(2001). Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer’s disease. Exp Neurol
(2004). Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRx
(2008). Conversion from cognitive health to mild cognitive impairment and Alzheimer’s disease: Prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol Aging
(2008). Core Team: R: A language and environment for statistical computing. R Foundation for Statistical Computing
(2003). Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA
(2006). Diagnostic criteria in dementia: a comparison of current criteria, research challenges, and implications for DSM-V.
(2007). Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology
(2008). Efficacy and safety of tarenflurbil in mild to moderate Alzheimer’s disease: a randomised phase II trial. Lancet Neurol
(1984). EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’sD i s e a s e .Neurology
(2002). et al: Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group. Neurobiol Aging
(2008). Forlenza OV: Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer’s disease? A systematic review and metaanalysis of the literature.
(2007). Grundke-Iqbal I: Developing pharmacological therapies for Alzheimer disease. Cell Mol Life Sci
(2002). H: CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology
(2006). Has the amyloid cascade hypothesis for Alzheimer’s disease been proved? Curr Alzheimer Res
(1999). Hedley-Whyte ET: Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease.
(2006). Humpel C: Measurement of thirteen biological markers in CSF of patients with Alzheimer’s disease and other dementias. Dement Geriatr Cogn Disord
ifultools: Insightful Research Tools.
(2000). Imahori K: CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol
(2005). Increased levels of CSF phosphorylated tau in apolipoprotein E ε4 carriers with mild cognitive impairment. Neurosci Lett
(2005). JB: Evaluation of selection bias in an incident-based dementia autopsy case series. Alzheimer Dis Assoc Disord
(2009). JC: Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging
(1997). JH: Neuropathological assessment of the lesions of significance in vascular dementia.
(2010). JQ: Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol
(2004). Jr: Back to the future: the ‘old-fashioned’ way to new medications for neurodegeneration. Nat Med
(2008). Kienzl E: Biomarkers for early diagnosis of Alzheimer disease: ‘ALZheimer ASsociated gene’–a new blood biomarker? J Cell Mol Med
(1991). L: The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology
(2007). Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry
(2005). Markesbery W: Recent clinical-pathologic research on the causes of dementia in late life: update from the Honolulu-Asia Aging Study.
(2007). Mevik B-H: ffmanova: Fifty-fifty MANOVA.
(2006). Mild cognitive impairment and the 7 uses of epidemiology. Alzheimer Dis Assoc Disord
(2006). Minghetti L: Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer’s disease.
(2006). Minthon L: Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol
(1996). Munroe WA: Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer’s disease.
(2010). Nonspecific binding of Ab42 to polypropylene tubes and the effect of Tween-20. Clin Chimica Acta
(2008). of 11effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet
(2005). Orgogozo JM: Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology
(2009). Rapid progression from mild cognitive impairment to Alzheimer’s disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/ epsilon4 genotype. Dement Geriatr Cogn Disord
(2006). Reboldi P: Diagnosing prodromal Alzheimer’s disease: role of CSF biochemical markers. Mech Ageing Dev
(2008). Shifts in thinking about dementia. JAMA
(2009). subjects: diagnostic discrimination and cognitive correlations. Neurology
(2003). Trojanowski JQ: Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsyconfirmed dementia diagnoses? Arch Neurol
(2008). Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree? J Am Geriatr Soc
(2004). Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer’s disease in patients with mild cognitive impairment. Mol Psychiatry
(2009). van der Flier WM: CSF biomarker levels in early and late onset Alzheimer’s disease. Neurobiol Aging
(2009). van der Flier WM: CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology
(2007). Younkin SG: Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol